Nyxoah SA
NASDAQ:NYXH 4:00:00 PM EDT
| Market Cap (Intraday) | 285.25M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.61 |
| 50-Day MA | $7.10 |
| 200-Day MA | $8.56 |
Nyxoah SA Stock, NASDAQ:NYXH
Rue Edouard Belin 12, Mont-Saint-Guibert, Walloon Region 1435
Belgium
Phone: +32.10.22.23.55
Number of Employees: 146.8
Description
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.